


(C₃-C₁₃)heterocyclylthio, (C₃-C₁₃)heterocyclyl-NR⁵-, hydroxy(C₁-C₁₀)alkyl, mercapto(C₁-C₆)alkyl, (NR⁵R⁶)alkyl, or (NR⁵R⁶)carbonyl; and R⁸ is absent or is (C₆-C₁₂)aryl, (C₆-C₁₂)aryl(C₁-C₆)alkyl, (C₃-C₈)cycloalkyl, (C₃-C₈)cycloalkyl(C₁-C₆)alkyl, (C₅-C₁₂)heteroaryl, (C₅-C₁₂)heteroaryl(C₁-C₆)alkyl, (C₃-C₁₃)heterocyclyl or
 5 (C₃-C₁₃)heterocyclyl(C₁-C₆)alkyl.

The instant invention provides new antibacterial 2*H*-indazole derivatives, namely the compounds of formula I described herein.

In one aspect, there is provided a compound of formula I



wherein



10


R¹ represents H or halogen;

R² represents (C₃-C₄)alkynyloxy or the group M;

R³ represents H or halogen;

M is one of the groups M^A, M^B, M^C and M^D represented hereafter





wherein A represents a bond, CH_2CH_2 , $\text{CH}=\text{CH}$ or $\text{C}\equiv\text{C}$;

$\text{R}^{1\text{A}}$ represents H or halogen;

$\text{R}^{2\text{A}}$ represents H, $(\text{C}_1\text{-C}_3)$ alkoxy or halogen;

$\text{R}^{3\text{A}}$ represents H, $(\text{C}_1\text{-C}_3)$ alkoxy, hydroxy $(\text{C}_1\text{-C}_4)$ alkoxy, $(\text{C}_1\text{-C}_3)$ alkoxy $(\text{C}_2\text{-C}_3)$ alkoxy, dihydroxy $(\text{C}_3\text{-C}_4)$ alkoxy, $(\text{C}_1\text{-C}_3)$ thioalkoxy, trifluoromethoxy, amino, di $(\text{C}_1\text{-C}_3)$ alkylamino, 2-hydroxyacetamido, hydroxy $(\text{C}_1\text{-C}_4)$ alkyl, 1-aminocyclopropyl, 1-hydroxymethyl-cycloprop-1-yl, *trans*-2-hydroxymethyl-cycloprop-1-yl, 1,2-dihydroxyethyl, 3-hydroxyoxetan-3-yl, 3-(hydroxy $(\text{C}_1\text{-C}_3)$ alkyl)oxetan-3-yl, 3-aminooxetan-3-yl, 3-(di $(\text{C}_1\text{-C}_3)$ alkylamino)oxetan-3-yl, 3-hydroxythietan-3-yl, morpholin-4-yl $(\text{C}_2\text{-C}_3)$ alkoxy, morpholin-4-yl- $(\text{C}_1\text{-C}_2)$ alkyl, oxazol-2-yl or [1,2,3]triazol-2-yl;

$\text{R}^{1\text{B}}$ represents 3-hydroxyoxetan-3-yl, 3-aminooxetan-3-yl, 3-hydroxythietan-3-yl, hydroxy $(\text{C}_1\text{-C}_3)$ alkyl, dihydroxy $(\text{C}_2\text{-C}_4)$ alkyl, amino $(\text{C}_1\text{-C}_4)$ alkyl, (dimethylamino)methyl, 1-hydroxymethyl-cycloprop-1-yl, *trans*-2-(1,2-dihydroxyethyl)cycloprop-1-yl, 1-((phosphonooxy)methyl)cyclopropyl, 1-(((dimethylglycyl)oxy)methyl)cyclopropyl, 1-methyl-2-hydroxymethyl-cycloprop-1-yl, 2-(hydroxymethyl)-2-methylcyclopropyl, 1-aminocyclopropyl, *trans*-2-hydroxymethyl-cycloprop-1-yl, *trans*-2-aminomethyl-cycloprop-1-yl, 1-fluoro-2-(hydroxymethyl)cyclopropyl, 2-fluoro-2-(hydroxymethyl)cyclopropyl, 1-(hydroxymethyl)cyclobutyl, 3-hydroxy-oxetan-3-yl, 3-hydroxymethyl-oxetan-3-yl, 1-(2-hydroxyacetyl)azetidin-3-yl, 1-(2-aminoacetyl)azetidin-3-yl, 1-glycylazetidin-3-yl, 1-(2-amino-2-methylpropanoyl)azetidin-3-yl, 3-(2-aminoacetamido)cyclopentyl, *trans*-(*cis*-3,4-dihydroxy)-cyclopent-1-yl, 3-hydroxymethylbicyclo[1,1,1]pentan-1-yl, piperidin-4-yl, 1-(2-hydroxyacetyl)piperidin-4-yl, 1-(2-aminoacetyl)piperidin-4-yl, 4-hydroxytetrahydro-2*H*-pyran-4-yl, 5-aminotetrahydro-2*H*-pyran-2-yl, (1*s*,3*r*)-(1-hydroxy-3-(hydroxymethyl)cyclobutyl)methyl or 3-hydroxyoxetan-3-ylmethyl;

and

R^{1C} represents 1-hydroxymethyl-cycloprop-1-yl, *trans*-2-(1,2-dihydroxyethyl)cycloprop-1-yl, 1-methyl-2-hydroxymethyl-cycloprop-1-yl, 2-(hydroxymethyl)-2-methylcyclopropyl, 1-aminocyclopropyl, *trans*-2-hydroxymethyl-cycloprop-1-yl, 1-fluoro-2-(hydroxymethyl)cyclopropyl or 2-fluoro-2-(hydroxymethyl)cyclopropyl;

5 or a salt of this compound.


In another aspect, there is provided a compound of formula I as defined herein, or a pharmaceutically acceptable salt thereof, for use as a medicament.

10 In yet another aspect, there is provided a pharmaceutical composition containing, as active principle, a compound of formula I as defined herein, or a pharmaceutically acceptable salt thereof, and at least one therapeutically inert excipient.

In a further aspect, there is provided a use of compound of formula I as defined herein, or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for the prevention or treatment of a bacterial infection.

Various embodiments of the invention are presented hereafter:

15 1) The invention relates to compounds of formula I



I

wherein

R^1 represents H or halogen;

R^2 represents (C₃-C₄)alkynyloxy or the group M;

R^3 represents H or halogen;

- (R)-4-(5-(6-amino-6-methylhepta-1,3-diyn-1-yl)-2*H*-indazol-2-yl)-*N*-hydroxy-2-methyl-2-(methylsulfonyl)butanamide;

- (R)-4-(5-((1-glycylpiperidin-4-yl)buta-1,3-diyn-1-yl)-2*H*-indazol-2-yl)-*N*-hydroxy-2-methyl-2-(methylsulfonyl)butanamide;

5 - (R)-4-(5-((1-glycylazetidin-3-yl)buta-1,3-diyn-1-yl)-2*H*-indazol-2-yl)-*N*-hydroxy-2-methyl-2-(methylsulfonyl)butanamide;

- (R)-4-(5-((1-(2-amino-2-methylpropanoyl)azetidin-3-yl)buta-1,3-diyn-1-yl)-2*H*-indazol-2-yl)-*N*-hydroxy-2-methyl-2-(methylsulfonyl)butanamide;

or a salt of this compound.

10 **14.** A compound of formula I as defined in one of claims 1 to 13, or a pharmaceutically acceptable salt thereof, for use as a medicament.

15. A pharmaceutical composition containing, as active principle, a compound of formula I as defined in one of claims 1 to 13, or a pharmaceutically acceptable salt thereof, and at least one therapeutically inert excipient.

15 **16.** ~~Use of A~~ compound of formula I as defined in one of claims 1 to 13, or a pharmaceutically acceptable salt thereof, for ~~use in~~ the manufacture of a medicament for the prevention or treatment of a bacterial infection.

20 ~~17. A compound or pharmaceutically acceptable salt~~ Use according to claim 16, which is for use in the prevention or treatment of wherein the bacterial infection is a Gram-negative bacterial infection.